You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Musculoskeletal conditions
  5. Arthritis

Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying anti-rheumatic drugs

  • Technology appraisal guidance
  • Reference number: TA225
  • Published:  22 June 2011
  • Guidance
  • Tools and resources
  • Information for the public
  • History

TA225 Rheumatoid arthritis (after the failure of previous anti-rheumatic drugs) - golimumab: Appendix B proposal paper presented to the Institute's Guidance Executive

TA225 Rheumatoid arthritis (after the failure of previous anti-rheumatic drugs) - golimumab: Appendix B proposal paper presented to the Institute's Guidance Executive TA225 Rheumatoid arthritis (after the failure of previous anti-rheumatic drugs) - golimumab: Appendix B proposal paper presented to the Institute's Guidance Executive
15 July 2013
(518.7 Kb 31 sec)

Adobe Acrobat reader required.

  Adobe Acrobat reader required.

This page was last updated: 11 July 2013

Back to top